GU Cancers 2025 | RC48-C017: disitamab vedotin and toripalimab in HER2-expressing MIBC
Xinan Sheng
• 10 Feb 2025
Xinan Sheng, MD, Peking University Cancer Hospital & Institute, Beijing, China, shares updated results from the Phase II RC48-C017 trial (NCT05297552) of disitamab vedotin and perioperative toripalimab in muscle-invasive bladder cancer (MIBC) with HER2 expression. Promising pathological complete response and event-free survival rates were observed, particularly in HER2 IHC 3+ patients. The safety profile was manageable with no surgery delays. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
